Abstract
Human embryonic stem cells (hESC) present a novel platform for in vitro investigation of the early embryonic cellular response to ionizing radiation. Thus far, no study has analyzed the genome-wide transcriptional response to ionizing radiation in hESCs, nor has any study assessed their ability to form teratomas, the definitive test of pluripotency. In this study, we use microarrays to analyze the global gene expression changes in hESCs after low-dose (0.4 Gy), medium-dose (2 Gy), and high-dose (4 Gy) irradiation. We identify genes and pathways at each radiation dose that are involved in cell death, p53 signaling, cell cycling, cancer, embryonic and organ development, and others. Using Gene Set Enrichment Analysis, we also show that the expression of a comprehensive set of core embryonic transcription factors is not altered by radiation at any dose. Transplantation of irradiated hESCs to immune-deficient mice results in teratoma formation from hESCs irradiated at all doses, definitive proof of pluripotency. Further, using a bioluminescence imaging technique, we have found that irradiation causes hESCs to initially die after transplantation, but the surviving cells quickly recover by 2 weeks to levels similar to control. To conclude, we show that similar to somatic cells, irradiated hESCs suffer significant death and apoptosis after irradiation. However, they continue to remain pluripotent and are able to form all three embryonic germ layers. Studies such as this will help define the limits for radiation exposure for pregnant women and also radiotracer reporter probes for tracking cellular regenerative therapies. Cancer Res; 70(13); 5539–48. ©2010 AACR.
Introduction
Ionizing radiation is a form of electromagnetic radiation produced by X-ray machines, fluoroscopy, radioactive isotopes, as well as nuclear environmental catastrophe. In pregnant mothers undergoing diagnostic or therapeutic procedures involving ionizing radiation, or who may be exposed to environmental radiation, there is a great potential for damage to the early embryo (1, 2). The current consensus is that exposure to radiation of <0.05 Gy during pregnancy is not related to an elevated risk of malformation, and many diagnostic procedures remain below this threshold (note that Gy is a unit of absorbed dose and reflects the amount of energy deposited into a mass of tissue; refs. 1, 3). However, these data are based on limited human data or on animal models and so may not accurately reflect the human embryonic response to radiation.
With the growing number of imaging procedures that use ionizing radiation, such as X-rays, computed tomographic (CT) scans (4–6), and positron emission tomography (PET) or single-photon emission CT, reporter probes that monitor stem cell transplantation for regenerative and antioncogenic therapies (7, 8), as well as concerns over terrorist attacks involving radioactive materials (9), there is a need to better understand the effects on human embryonic stem cells (hESC). A number of reports have studied both UV- and γ-irradiated mouse (10–12) and human (13–17) embryonic stem cells, and have primarily focused on the DNA damage response such as cell cycling, p53 signaling, and apoptosis. Only two (14, 17) have attempted to characterize the effects of radiation on the defining feature of hESCs: pluripotency, or ability to form all three embryonic germ layers. However, these studies focused on the expression of just two embryonic genes (Oct4 and Nanog) after irradiation, and none have performed teratoma studies to prove pluripotency.
To address this lack of knowledge, we perform gene expression profiling of irradiated hESCs at three different doses, allowing us to analyze global pluripotency programs that may be affected by radiation. Taking advantage of novel molecular imaging techniques to track hESC proliferation, we also inject irradiated hESCs into mice and show that despite a transient decrease in cellular proliferation with the highest dose used in this study (4 Gy), these cells are still able to ultimately form teratomas. Taken together, we present definitive proof that hESCs that survive irradiation up to 4 Gy are pluripotent.
Materials and Methods
hESC culture
Undifferentiated hESCs (H9 line from Wicell, passages 45–55) were grown on Matrigel-coated plates in mTeSR1 medium (Stem Cell Technologies) as previously described (18). Cell medium was changed daily and passaged approximately every 4 to 6 days using collagenase IV. For cell counting, hESC colonies were digested to single cells with 0.05% trypsin EDTA and counted with a Countess Automated Cell Counter (Invitrogen).
Irradiation
hESCs were irradiated with 0.4, 2, or 4 Gy of γ-radiation using a cesium-137 irradiator. Immediately after irradiation, cells were returned to the incubator for recovery until the appropriate time point.
Reverse transcription-PCR
18S was used as housekeeping gene control. The primer sets used in the amplification reaction are as follows: human CXCL10(IP10), 5′-CTGATTTGCTGCCTTATCTTTCT-3′ (forward) and 5′-ACATTTCCTTGCTAACTGCTTTC-3′ (reverse); human GADD45, 5′-TGGAGGAAGTGCTCAGCAAAGCC-3′ (forward) and 5′-ACGCCTGGATCAGGGTGAAGTGG-3′ (reverse); and human 18S, 5′-ACACGGACAGGATTGACAGA-3′ (forward) and 5′-GGACATCTAAGGGCATCACAG-3′ (reverse).
Immunohistochemical analysis
Forty-eight hours after irradiation, hESCs were fixed with 2% formaldehyde in PBS for 2 minutes, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes, and blocked with 5% bovine serum albumin in PBS for an hour. Cells were then stained with appropriate primary antibodies and Alexa Fluor–conjugated secondary antibodies (Invitrogen). The primary antibodies for Oct4 (Santa Cruz Biotechnology), Sox2 (Biolegend), Nanog (Santa Cruz Biotechnology), SSEA4 (Chemicon), TRA-1-60 (Chemicon), and TRA-1-81 (Chemicon) were used in the staining.
Annexin V flow cytometry analysis
Forty-eight hours after irradiation, hESCs were harvested and resuspended in binding buffer and stained with 5 μL of Annexin V–FITC and 5 μL of propidium iodide (PI) using the Annexin V-FITC Apoptosis Detection Kit II (BD Pharmingen). The cell suspension was incubated for 15 minutes at room temperature and analyzed on a FACScan flow cytometer (BD Biosciences). Flow cytometry data were analyzed with FlowJo (Treestar) analysis software.
Microarray hybridization and data acquisition
Total RNA samples were isolated in Trizol (Invitrogen) followed by purification over an RNeasy column (Qiagen) from hESCs 48 hours after irradiation. Three independent experiments for each radiation group plus control (for a total of 12 unique samples) were harvested for RNA isolation. Using Agilent Low RNA Input Fluorescent Linear Amplification kits, cDNA was reverse transcribed from each of 12 RNA samples representing four biological triplicates, as well as the pooled reference control, and cRNA was then transcribed and fluorescently labeled with Cy5/Cy3. cRNA was purified using an RNeasy kit. Cy3- and Cy5-labeled and amplified cRNA (825 ng) was hybridized to Agilent 4x44K whole human genome microarrays (G4112F) and processed according to the manufacturer's instructions. The array was scanned using Agilent G2505B DNA microarray scanner. The image files were extracted using Agilent Feature Extraction software version 9.5.1 applying LOWESS background subtraction and dye normalization.
The data were analyzed using GeneSpring GX 10.0 (Agilent Technologies) to identify genes that had statistically significantly changed expression between groups. Genes were considered significantly differentially regulated with P value of <0.05 and fold change of ≥1.4. For hierarchical clustering, we used Pearson correlation for similarity measure and average linkage clustering. A heat map was generated using Pearson correlation clustering of a significant gene list after one-way ANOVA of the raw data from all four groups.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) was performed using the GeneSpring GX software and gene sets downloaded from Molecular Signatures Database (MSigDB; Broad Institute, Massachusetts Institute of Technology); a custom list of 26 pluripotency genes was also created based on literature review. Gene sets were considered significant with Q value of <0.25, as recommended (19). Briefly, the primary result of GSEA is the enrichment score (ES), which reflects the degree to which a gene set is overrepresented at the top or bottom of a ranked list of genes. The normalized ES (NES) is the primary statistic for examining gene set enrichment results. By normalizing the ES, GSEA accounts for differences in gene set size and in correlations between gene sets and the expression data set.
Ingenuity Pathway Analysis
Significant gene lists were generated from the GeneSpring software and uploaded to Ingenuity Pathway Analysis (IPA) for analysis. IPA assigns biological functions to genes using the Ingenuity Pathways Knowledge Base (Ingenuity Systems, Inc.). This information is used to form networks to create an “interactome” of genes that are involved in specific biological processes.
Functional analysis
The Functional Analysis identified the biological functions and/or diseases that were most significant to the data set. Molecules from the data set that met the P value cutoff of 0.05 and fold change cutoff of 1.4 were then associated with biological functions and/or diseases in Ingenuity's Knowledge Base. Right-tailed Fisher's exact test was used to calculate a P value determining the probability that each biological function and/or disease assigned to that data set is due to chance alone.
Canonical pathway analysis
Canonical pathway analysis identified the pathways from the Ingenuity Pathways Analysis library of canonical pathways that were most significant to the data set. The significance of the association between the data set and the canonical pathway was measured in two ways. (a) A ratio of the number of molecules from the data set that map to the pathway divided by the total number of molecules that map to the canonical pathway is displayed. (b) Fisher's exact test was used to calculate a P value determining the probability that the association between the genes in the data set and the canonical pathway is explained by chance alone.
Generation of stable reporter gene hESC lines
Enhanced green fluorescent protein (eGFP) and firefly luciferase (Fluc) double-fusion reporter gene–positive hESCs (Fluc+/eGFP+hESC) have been previously described (20, 21). Briefly, SIN lentivirus was prepared by transient transfection of 293T cells. H9 hESCs were stably transduced with LV-pUB-Fluc-eGFP at a multiplicity of infection of 10. The infectivity was determined by eGFP expression as analyzed on a FACScan. eGFP-positive cell populations were isolated by FACSVantage SE cell sorter (Becton Dickinson), followed by plating for long-term culture.
Subcutaneous transplantation of hESCs
Animal protocols were approved by the Stanford University Animal Care and Use Committee guidelines. All procedures were performed on 8- to 10-week-old female severe combined immunodeficient (SCID) Beige mice (Charles River Laboratories). Following induction with inhaled isoflurane (2–3%), anesthesia was then maintained with 1% to 2.5% isoflurane. Two hundred thousand Fluc+/eGFP+hESCs were suspended in a 50 μL volume of a 1:1 mixture of growth factor–reduced Matrigel and DMEM and then irradiated at the appropriate dosage (0.4, 2, or 4 Gy). Irradiated cell suspensions were each injected s.c. into the dorsum of eight SCID mice; injections were performed within 2 hours of irradiation.
Bioluminescence imaging of transplanted cell survival
Bioluminescence imaging (BLI) was performed using the Xenogen IVIS 200 system (Caliper Life Sciences). After i.p. injection of the reporter probe d-luciferin (375 mg luciferin/kg body weight), animals were imaged for 1 to 10 minutes. The same mice were imaged for 6 weeks. Regions of interest were drawn over the signals using the Igor image analysis software (Wavemetrics). BLI signal was standardized for acquisition time and quantified in units of maximum photons per second per square centimeter per steridian (photons/s/cm2/sr), as described (22).
Postmortem immunohistochemical staining
Animals were sacrificed according to protocols approved by the Stanford Animal Research Committee after the duration of the study. Teratomas were explanted and processed for H&E staining. Slides were interpreted by an expert pathologist (A.J.C.).
Statistical analysis
Nonmicroarray data are presented as mean ± SD. Data were compared using standard or repeated-measures ANOVA, where appropriate. Differences were considered significant for P < 0.05.
Results
Figure 1A gives a schematic of our experimental design. We first confirmed that low-dose irradiation (<1 Gy) of hESCs was capable of upregulating known stress-responsive genes: GADD45, which mediates activation of the p38/c-Jun NH2-terminal kinase pathway via MTK1/MEKK4 kinase, and CXCL10, a chemokine for receptor CXCR3 that is involved in recruitment of inflammatory cells (Supplementary Fig. S1). At a higher dose of 4 Gy, we observed massive cell death that was concurrent with the development of holes and patchy regions in hESC colonies at 48 hours (Fig. 1B and C); hole formation has also been reported in colonies 6 hours after 5 Gy irradiation (14). However, the surviving hESCs continued to express common pluripotency markers, such as TRA-1-81, SSEA4, and TRA-1-60, and embryonic transcription factors, such as Oct4, Sox2, and Nanog, which are key regulators of pluripotency and self-renewal (Fig. 1C).
We were curious about the relative extent of apoptosis and cell death after irradiation at the different dosages, and so we double stained hESCs with Annexin V (early apoptosis) and PI (cell death) 48 hours after irradiation and analyzed the cells with flow cytometry (Fig. 1D). Clearly, there is a trend toward increasing apoptosis and cell death at the higher radiation doses (2 and 4 Gy) compared with low dose (0.4 Gy) and control. The majority (>70%) of hESCs are dead after 4 Gy irradiation, although an apoptotic minority (<30%) seems to survive at 48 hours. This latter population likely represents the surviving cells that continue to express pluripotency markers, as seen in Fig. 1C. However, the definitive test of pluripotency of human cells is the ability to form a teratoma, which we performed next.
To confirm that surviving hESCs are pluripotent, we injected irradiated cells into immunocompromised mice and monitored for teratoma formation. We tracked their growth kinetics in vivo by using hESCs that constitutively express a Fluc-eGFP double-fusion reporter gene (Fig. 2A), enabling longitudinal monitoring of cellular photon emission, and by extension their proliferation, as described (20, 21). After irradiation and injection of Fluc+/eGFP+hESCs, we found that photon emission from the 2 and 4 Gy groups reached a statistical minimum at 7 days that was less than photon emission from cells exposed to 0 and 0.4 Gy, suggesting massive cell death (P < 0.05; n = 8 per group; see Fig. 2B and C). Based on the photon intensities, we estimated that 38 ± 30%, 63 ± 20%, 80 ± 9%, and 83 ± 7% (mean ± SE) of the 0 Gy–, 0.4 Gy–, 2 Gy–, and 4 Gy–irradiated cells, respectively, had died at day 7.
We expected that the 2 and 4 Gy groups would continue to die, but surprisingly, all four groups emitted similar levels of photons by day 21, indicating that surviving hESCs had recovered from high-dose irradiation. We confirmed this result by studying long-term in vitro cultures of irradiated hESCs and found that cell proliferation was inhibited in the first week after high-dose irradiation, but thereafter, all groups exhibited similar growth kinetics (Supplementary Fig. S2). Note that after the postirradiation “recovery period,” we did not observe any compensatory increase in cell proliferation in the high-dose groups. Finally, of the eight mice used in this study, five developed teratomas in the 4 Gy group by the sixth week (see Fig. 2D for representative H&E images and Supplementary Fig. S3 for a representative gross image of four teratomas from a single mouse). The three mice that failed to form teratomas in the 4 Gy group likely experienced significant apoptosis and cell death and not loss of pluripotency. To confirm this, we performed a careful microarray study of the core set of pluripotency genes to determine whether there are any detectable changes in pluripotency programs, however subtle, in response to ionizing radiation.
For the transcriptomic analysis of irradiated hESCs, RNA was isolated from cells 24 hours after irradiation and then labeled and hybridized to microarrays (raw data files have been uploaded to Gene Expression Omnibus under accession number GSE20951). When analyzing microarray data, it is often informative to start from a system-wide rather than individual-gene view of the resulting data, especially when the overall gene fold changes are no more than 7-fold (Supplementary Table S1). An overview of the gene profiles can be seen in the heat map of Fig. 3A. Most apparent is the coclustering of the control and low-dose samples (0 and 0.4 Gy), which were distinct from the coclustering of the high-dose samples (2 and 4 Gy). This pattern is also evident in Table 1, in which global Pearson correlation shows 95% correlation between the 2 and 4 Gy groups but only 86% correlation with the low-dose 0.4 Gy group. A Venn diagram of the entities that are significantly different (P < 0.05; fold change ≥ 1.4) between radiation dosage and control further illustrates this pattern (Fig. 3B; note that microarrays often contain multiple probes, or “entities,” for a given gene). Again, we observe the same grouping as in the Pearson correlation: the 2 Gy– and 4 Gy–irradiated samples exhibit a higher degree of overlap between themselves than they do with the 0.4 Gy group.
Gy . | 0 . | 0.4 . | 2 . | 4 . |
---|---|---|---|---|
0 | 1 | |||
0.4 | 0.91 | 1 | ||
2 | 0.87 | 0.86 | 1 | |
4 | 0.89 | 0.86 | 0.95 | 1 |
Gy . | 0 . | 0.4 . | 2 . | 4 . |
---|---|---|---|---|
0 | 1 | |||
0.4 | 0.91 | 1 | ||
2 | 0.87 | 0.86 | 1 | |
4 | 0.89 | 0.86 | 0.95 | 1 |
We next used IPA (Ingenuity Systems, http://www.ingenuity.com) and GSEA (19) to further analyze the microarray data. Selected canonical pathways and functions that are disrupted after 4 Gy irradiation (versus control) are summarized in Table 2; full data sets can be found in Supplementary Tables S2 and S3. After 4 Gy irradiation, canonical pathways, such as VDR/retinoid X response (RXR) activation, p53 signaling, and aryl hydrocarbon signaling, and functions, such as cancer, cell death, cell cycle, growth and proliferation, and embryonic development, are significantly affected in hESCs. Specifically, several tumor protein p53–associated genes such as TP53INP1 (up 2.6-fold) and target genes such as CDKN1A (up 2-fold) and MDM2 (up 1.7-fold; ref. 23), as well as several tumor necrosis factor receptor superfamily members, were disregulated after irradiation. A small group of genes associated with development also exhibited differential expression, including HES1 (down 1.8-fold; ref. 24), RUNX1 (up 1.5 fold), and PBX1 (down 1.8-fold); note that many of these genes are also associated with cancer (Table 2). Supporting the observation that genes related to cancer are disregulated with radiation, GSEA, a method for analyzing a priori gene sets within microarray data, revealed upregulation of gene sets that have also been reported in cells after treatment with chemotherapeutic drugs (Table 3; refs. 25–27).
Canonical pathways . | Genes . |
---|---|
VDR/RXR activation | IGFBP6, CDKN1A, CSNK2A1, HES1, RXRB, PRKCB |
p53 signaling | TP53INP1, CDKN1A, TNFRSF10B, C12ORF5, MDM2, HIPK2 |
Aryl hydrocarbon receptor signaling | TFF1, NQO1, CDKN1A, MDM2, DHFR, RXRB, AHR |
Platelet-derived growth factor signaling | CSNK2A1, INPP5D, PRKCB |
Notch signaling | DTX1, HES1 |
Cell cycle: G2-M DNA damage: checkpoint regulation | CDKN1A, MDM2 |
Molecular mechanisms of cancer | HHAT, RALA, CDKN1A, MDM2, HIPK2, GLI1, FAS, PRKCB |
Functions | Genes |
Cancer | DPYD, PLK3, PBX1, EIF4A2, ATP4A, HES1, DDB2. LATS2, TTC22, FHL2, TFF1, MPHOSPH8, NEK6, CSNK2A1, TNFRSF10C, CBFB, TUBA1C, TTC5, HIPK2, CDKN1C, AHR, MYO6, IGFBP6, IFIT3, TUBB3, TP53INPL, NKTR, PPP1R1B, TNFRSF10B, LlCAM, UBE2S, RASD1, CD40, MIB1, LRP8, RUNX1, DHFR, HELB, EB13, RPL13A, KIAA1370, POLE3, FBXL7, PIAS1, GDF15, FAS, STK17A, GBP2, RXRB, VASP, CALR, ATP1B1, CKM, NQO1, TOB1, MDM2, SLC7A8, FDXR, INPP5D, DNM1, TRPM6, HP, GMPS, CDKN1A, MEF2C, GLI1, COBLL1, POLH, PRKCB |
Cell death | QKI, PLK3, PBX1, DDB2, HES1, TREM2, LATS2, FHL2, BLOC1S2, TFF1, MTF1, NEK6, CSNK2A1, CBFB, TTC5, TNFRSF10C, CDKN1C, HIPK2, AHR, MYO6, SHISA5, IGFBP6, TUBB3, TP53INP1, SGCG, PPP1R1B, TNFRSF10B, L1CAM, UBE2S, LAX1, RASD1, NCF1, MNT, CD40, MIB1, RUNX1, GDF15, PIAS1, FAS, STK17A, RPS3, SOX5, CALR, THG1L, NQO1, CDC42EP3, MDM2, INPP5D, FDXR, DNM1, CDKN1A, MEF2C, GLI1, PRKCB, POLH |
Cell morphology | RALA, PLK3, GDF15, ATP4A, HES1, LATS2, FAS, ANK1, MACF1, CSNK2A1, CBFB, CDKN1C, RXRB, VASP, VASP, AHR, PRICLE2, TNFRSF10B, MDM2, LICAM, DNM1, PIP5K1A, CD40, MIB1, CDKN1A, FOXJ1, B3GAT1, LRP8, NDST2, GLI1 |
Cellular assembly and organization | RALA, TUBGCP3, NQO1, TNFRSF10B, PLEC1, MDM2, FAS, ANK1, DNM1, TUBGCP5, RAB11FIP4, AMPH, CDKN1A, TTL, NDST2, CDKN1C, VASP, AHR |
Embryonic development | TP53INP1, PIAS1, TNFRSF10B, PBX1, LICAM, HES1, FAS, DNM1, MTF1, RUNX1, HIPK2, GLI1, VASP, AHR |
Cellular growth and proliferation | GDF15, PIAS1, PBX1, HES1, FAS, FHL2, HS6ST2, CBFB, CDKN1C, HIPK2, VASP, AHR, CALR, IGFBP6, TUBB3, TP53INP1, TNFRSF10B, TOB1, PTP4A1, MDM2, INPP5D, TRPM6, NCF1, MNT, CD40, CDKN1A, UHMK1, DHFR, RUNX1, GLI1, PRKCB |
Cell cycle | CALR, TP53INP1, GDF15, PIAS1, MDM2, HES1, LATS2, INPP5D, FAS, DNM1, SESN1, MNT, CD40, CDKN1A, NEK6, CSNK2A1, UHMK1, RUNX1, CDKN1C, HIPK2, AHR |
Cellular development | QK1, PBX1, HES1, TREM2, FAS, ANK1, FOXN4, FHL2, DTX1, TFF1, CBFB, CDKN1C, RXRB, AHR, VASP, SOX5 (includes EG:6660), MYO6, IGFBP6, CALR, CTSK, TUBB3, PPP1R1B, DNER, TNFRSF10B, TOB1, L1CAM, MDM2, INPP5D, NCF1, MNT, CD40, MIB1, CDKN1A, MEF2C, RUNX1, GLI1, PRKCB |
Canonical pathways . | Genes . |
---|---|
VDR/RXR activation | IGFBP6, CDKN1A, CSNK2A1, HES1, RXRB, PRKCB |
p53 signaling | TP53INP1, CDKN1A, TNFRSF10B, C12ORF5, MDM2, HIPK2 |
Aryl hydrocarbon receptor signaling | TFF1, NQO1, CDKN1A, MDM2, DHFR, RXRB, AHR |
Platelet-derived growth factor signaling | CSNK2A1, INPP5D, PRKCB |
Notch signaling | DTX1, HES1 |
Cell cycle: G2-M DNA damage: checkpoint regulation | CDKN1A, MDM2 |
Molecular mechanisms of cancer | HHAT, RALA, CDKN1A, MDM2, HIPK2, GLI1, FAS, PRKCB |
Functions | Genes |
Cancer | DPYD, PLK3, PBX1, EIF4A2, ATP4A, HES1, DDB2. LATS2, TTC22, FHL2, TFF1, MPHOSPH8, NEK6, CSNK2A1, TNFRSF10C, CBFB, TUBA1C, TTC5, HIPK2, CDKN1C, AHR, MYO6, IGFBP6, IFIT3, TUBB3, TP53INPL, NKTR, PPP1R1B, TNFRSF10B, LlCAM, UBE2S, RASD1, CD40, MIB1, LRP8, RUNX1, DHFR, HELB, EB13, RPL13A, KIAA1370, POLE3, FBXL7, PIAS1, GDF15, FAS, STK17A, GBP2, RXRB, VASP, CALR, ATP1B1, CKM, NQO1, TOB1, MDM2, SLC7A8, FDXR, INPP5D, DNM1, TRPM6, HP, GMPS, CDKN1A, MEF2C, GLI1, COBLL1, POLH, PRKCB |
Cell death | QKI, PLK3, PBX1, DDB2, HES1, TREM2, LATS2, FHL2, BLOC1S2, TFF1, MTF1, NEK6, CSNK2A1, CBFB, TTC5, TNFRSF10C, CDKN1C, HIPK2, AHR, MYO6, SHISA5, IGFBP6, TUBB3, TP53INP1, SGCG, PPP1R1B, TNFRSF10B, L1CAM, UBE2S, LAX1, RASD1, NCF1, MNT, CD40, MIB1, RUNX1, GDF15, PIAS1, FAS, STK17A, RPS3, SOX5, CALR, THG1L, NQO1, CDC42EP3, MDM2, INPP5D, FDXR, DNM1, CDKN1A, MEF2C, GLI1, PRKCB, POLH |
Cell morphology | RALA, PLK3, GDF15, ATP4A, HES1, LATS2, FAS, ANK1, MACF1, CSNK2A1, CBFB, CDKN1C, RXRB, VASP, VASP, AHR, PRICLE2, TNFRSF10B, MDM2, LICAM, DNM1, PIP5K1A, CD40, MIB1, CDKN1A, FOXJ1, B3GAT1, LRP8, NDST2, GLI1 |
Cellular assembly and organization | RALA, TUBGCP3, NQO1, TNFRSF10B, PLEC1, MDM2, FAS, ANK1, DNM1, TUBGCP5, RAB11FIP4, AMPH, CDKN1A, TTL, NDST2, CDKN1C, VASP, AHR |
Embryonic development | TP53INP1, PIAS1, TNFRSF10B, PBX1, LICAM, HES1, FAS, DNM1, MTF1, RUNX1, HIPK2, GLI1, VASP, AHR |
Cellular growth and proliferation | GDF15, PIAS1, PBX1, HES1, FAS, FHL2, HS6ST2, CBFB, CDKN1C, HIPK2, VASP, AHR, CALR, IGFBP6, TUBB3, TP53INP1, TNFRSF10B, TOB1, PTP4A1, MDM2, INPP5D, TRPM6, NCF1, MNT, CD40, CDKN1A, UHMK1, DHFR, RUNX1, GLI1, PRKCB |
Cell cycle | CALR, TP53INP1, GDF15, PIAS1, MDM2, HES1, LATS2, INPP5D, FAS, DNM1, SESN1, MNT, CD40, CDKN1A, NEK6, CSNK2A1, UHMK1, RUNX1, CDKN1C, HIPK2, AHR |
Cellular development | QK1, PBX1, HES1, TREM2, FAS, ANK1, FOXN4, FHL2, DTX1, TFF1, CBFB, CDKN1C, RXRB, AHR, VASP, SOX5 (includes EG:6660), MYO6, IGFBP6, CALR, CTSK, TUBB3, PPP1R1B, DNER, TNFRSF10B, TOB1, L1CAM, MDM2, INPP5D, NCF1, MNT, CD40, MIB1, CDKN1A, MEF2C, RUNX1, GLI1, PRKCB |
Gene set name . | P . | Q . | ES . | NES . | Description . | Genes in set . |
---|---|---|---|---|---|---|
METHOTREXATE_PROBCELL_UP | <0.0001 | 0.1447 | 0.6866 | 1.8669 | Upregulated in pro-B cells (FL5.12) following treatment with methotrexate (Brachat et al.) | ABI1, ABLIM1, CARHSP1, CASP4, CDKN1A, EI24, H2AFJ, LPIN1, LRRC2, MALAT1, MDM2, PVRI4, SLC7A14, TOB1, TP53INP1, TRAFD1, TXNIP, UCHL5 |
BLEO_HUMAN_LYMPH_HIGH_4HRS_UP | <0.0001 | 0.1929 | 0.7732 | 1.8725 | Upregulated at 4 h following treatment of human lymphocytes (TK6) with a high dose of bleomycin (Islaih et al.) | BBC3, BTG1, BTG2, CDKN1A, CLK1, DDB2, DDIT4, DUSP14, ENC1, FAS, FDXR, GADD45A, GDF15, HNRPA1, IER3, PLXNB2, PMAIP1, PPM1D, TNFRSF10B, TNFSF9, XPC |
CAMPTOTHECIN_PROBCELL_UP | <0.0001 | 0.2290 | 0.6617 | 1.8162 | Upregulated in pro-B cells (FL5.12) following treatment with camptothecin (Brachat et al.) | ABI1, C12ORF22, C1R, CARHSP1, CBS, CDKN1A, EI24, GRB10, H2AFJ, LPIN1, LRRC2, NUDCD2, PMM1, PVRL4, SERTAD1, SLC7A14, YTOB1, TP53INP1, TPP1, TRAFD1, TXNIP, UCHL5, ULK1 |
OXSTRESS_BREASTCA_UP | <0.0001 | 0.2314 | 0.7095 | 1.8060 | Upregulated by H2O2, menadione, and t-butyl hydroperoxide in breast cancer cells (Chuang et al.) | C1ORF107, CTAGE5, CYP1B1, DDTT3, DKK1, EDN1, EGR1, EPS8L2, FAS, FDXR, GDF15, H19, HMOX1, HSPA1B, JUN, LIF, LRP6, MT1H, MT1X, NQO1, PLA2R1, PPP2CB, PSITPTE22, PSMD12, PSMD3, RCBTB1, RPL38, SLC35B3, ZBTB4 |
Human Embryonic Cell Markers | 0.4000 | 0.5000 | −0.3177 | −1.0009 | Common hESC genes (based on literature search) | POU5F1, NANOG, KLF2, KLF5, SOX1, SOX2, SOX5, LIN28, DNMT3B, GDF3, DPPA4, DPPA5, ESRRG, SALL4, NR6A1, TDGF1, TBX3, FOXD3, FGF4, ZFP42, LEFTY1, LEFTY2, ERAS, PODXL, TERT, UTF1 |
Gene set name . | P . | Q . | ES . | NES . | Description . | Genes in set . |
---|---|---|---|---|---|---|
METHOTREXATE_PROBCELL_UP | <0.0001 | 0.1447 | 0.6866 | 1.8669 | Upregulated in pro-B cells (FL5.12) following treatment with methotrexate (Brachat et al.) | ABI1, ABLIM1, CARHSP1, CASP4, CDKN1A, EI24, H2AFJ, LPIN1, LRRC2, MALAT1, MDM2, PVRI4, SLC7A14, TOB1, TP53INP1, TRAFD1, TXNIP, UCHL5 |
BLEO_HUMAN_LYMPH_HIGH_4HRS_UP | <0.0001 | 0.1929 | 0.7732 | 1.8725 | Upregulated at 4 h following treatment of human lymphocytes (TK6) with a high dose of bleomycin (Islaih et al.) | BBC3, BTG1, BTG2, CDKN1A, CLK1, DDB2, DDIT4, DUSP14, ENC1, FAS, FDXR, GADD45A, GDF15, HNRPA1, IER3, PLXNB2, PMAIP1, PPM1D, TNFRSF10B, TNFSF9, XPC |
CAMPTOTHECIN_PROBCELL_UP | <0.0001 | 0.2290 | 0.6617 | 1.8162 | Upregulated in pro-B cells (FL5.12) following treatment with camptothecin (Brachat et al.) | ABI1, C12ORF22, C1R, CARHSP1, CBS, CDKN1A, EI24, GRB10, H2AFJ, LPIN1, LRRC2, NUDCD2, PMM1, PVRL4, SERTAD1, SLC7A14, YTOB1, TP53INP1, TPP1, TRAFD1, TXNIP, UCHL5, ULK1 |
OXSTRESS_BREASTCA_UP | <0.0001 | 0.2314 | 0.7095 | 1.8060 | Upregulated by H2O2, menadione, and t-butyl hydroperoxide in breast cancer cells (Chuang et al.) | C1ORF107, CTAGE5, CYP1B1, DDTT3, DKK1, EDN1, EGR1, EPS8L2, FAS, FDXR, GDF15, H19, HMOX1, HSPA1B, JUN, LIF, LRP6, MT1H, MT1X, NQO1, PLA2R1, PPP2CB, PSITPTE22, PSMD12, PSMD3, RCBTB1, RPL38, SLC35B3, ZBTB4 |
Human Embryonic Cell Markers | 0.4000 | 0.5000 | −0.3177 | −1.0009 | Common hESC genes (based on literature search) | POU5F1, NANOG, KLF2, KLF5, SOX1, SOX2, SOX5, LIN28, DNMT3B, GDF3, DPPA4, DPPA5, ESRRG, SALL4, NR6A1, TDGF1, TBX3, FOXD3, FGF4, ZFP42, LEFTY1, LEFTY2, ERAS, PODXL, TERT, UTF1 |
NOTE: GSEA of the same microarray data.
We have also analyzed the progression of gene and pathway changes that occur in hESCs at each increasing radiation dose: between 0 and 0.4 Gy (Supplementary Tables S4–S6), 0.4 and 2 Gy (Supplementary Tables S7–S9), and 2 and 4 Gy (Supplementary Tables S10–S12). Similar to 4 Gy radiation, 0.4 Gy irradiation affects cellular functions such as cell death, cancer, and signaling pathways such as p53, although not important p53 downstream target genes such as CDKN1A and MDM2. Because CDKN1A is an important negative regulator of cell cycling (28), the lack of upregulation of CDKN1A by 0.4 Gy irradiation could partly explain why we did not observe a similar reduction in cell proliferation as in the 2 and 4 Gy groups. Relative to 0.4 Gy irradiation, 2 Gy irradiation affects canonical transforming growth factor-β and Wnt/β-catenin signaling, including the genes Tgfbr2 (up 1.4-fold), Wnt1 (up 1.4-fold), Wnt10A (up 2.1-fold), and Wnt9a (up 1.8-fold); notably, Wnt proteins play important and diverse roles in embryonic stem cells (29). Irradiation (2 Gy) also induces CDKN1A upregulation by 2.3-fold but not MDM2. Interestingly, many genes involved in functions such as cellular compromise, amino acid metabolism, molecular transport, and cell morphology, in addition to cancer and cell death, were significantly disrupted by 2 Gy of radiation, including a number of solute carrier family proteins such as Slc6a13 (up 2-fold) and Slc25a13 (down 2.2-fold). Clearly, there is an overall significant increase in cellular dysfunction after 2 Gy irradiation, which explains the results from our in vivo and in vitro studies (Figs. 1 and 2). Finally, in the 2 Gy versus 4 Gy group, the overall gene changes were not large, but a small group of genes related to organ and tissue development did have altered expression, such as Tnfsf11 (up 1.6-fold), Otx1 (down 1.6-fold), B4galt1 (down 1.4-fold), and Mef2c (up 1.9-fold). Presumably, there are subtle development and differentiation processes that are activated with 4 Gy irradiation but are not robust enough to cause loss of pluripotency, as evidenced by successful formation of teratomas from 4 Gy-irradiated hESCs. Furthermore, the gene expression profiles of irradiated cells showed no increased correlation with previously reported data for differentiated hESCs and primary cell types (20, 30, 31), giving additional evidence that differentiation is not significantly increased with ionizing radiation (Supplementary Fig. S4).
With these observations, we were particularly interested to understand whether core pluripotency genes were also affected by radiation. Importantly, well-known embryonic transcription factors such as Oct4 (Pou5f1), Sox2, and Nanog, which are expressed exclusively or predominantly in hESCs and are critical for maintaining pluripotency and self-renewal, were not present in any of our significant gene lists across all radiation dosages. Moving beyond individual genes, we created a gene set of 26 known factors that are well known to be specific to hESCs (bottom row of Table 3). GSEA revealed no significant upregulation or downregulation of this set in the microarray data for the highest radiation dose, 4 Gy (P = 0.4; Q = 0.5; NES = −1.0). This finding agrees with a previous report that showed normalization of Oct4 and Nanog after only 24 hours in 2 Gy–irradiated hESCs (14). We therefore conclude that pluripotency gene programs are not significantly affected by high-dose radiation, and this accounts for the observation that surviving hESCs are still capable of forming all three embryonic germ layers.
Discussion
In pregnant mothers undergoing diagnostic or therapeutic procedures involving ionizing radiation, or who may be exposed to environmental radiation, there is a great potential for damage to the early embryo. Although the embryo is somewhat protected by the uterus, it is particularly sensitive to ionizing radiation, and the developmental consequences can be quite serious (2). Data about the potential biological effects on the embryo after in utero irradiation are based on the results of animal studies (32–35) and a limited number of human exposures such as the 1945 atomic bomb survivors from Hiroshima and Nagasaki. Based on these collective data, it has been well established that the dose of ionizing radiation and the developmental stage of the embryo are the determining factors for reproductive toxicity in embryonic development (1). Above poorly defined threshold doses, the major effects of ionizing radiation are lethality during the preimplantation-preorganogenetic period and malformations and growth retardation during organogenesis (1, 3). Other sequelae later in life may include severe mental retardation, a reduced intelligence quotient, and childhood cancer (1, 3, 36). Unfortunately, the absolute incidence and radiation dose at which these changes occur, as well as the mechanisms of damage, remain unclear.
Because the in utero embryonic response to ionizing radiation is not well understood due to the obvious ethical concerns of exposing pregnant mothers to radiation, hESCs present a novel in vitro platform for studying the human embryonic response to irradiation. These cells are derived from the inner cell mass of the blastocyst during embryonic development and are therefore closely related to the early-stage human embryo. Admittedly, hESCs are still different from the early embryo in that they lack the complex and dynamic signaling environment of the uterus and are instead maintained long term in relatively simple in vitro cultures. However, the advantage is that we can begin to tease out the embryonic response to irradiation in a human rather than murine system. Furthermore, because radiotracers and PET reporter genes that monitor cellular transplantation for emerging regenerative and antioncogenic therapies are being increasingly used in laboratory research (8), and one day may even achieve routine clinical application (7), it will be important to determine whether such radioactive probes can directly affect the viability and function of the transplanted cells. For these reasons, we decided that a broad survey of the functional and global molecular response of hESCs to irradiation, and in particular the effect of radiation on pluripotency, was a critical area of investigation.
Not surprisingly, our results show that high doses of radiation cause massive cell death, with a trend toward increasing apoptosis and death at the higher radiation doses (2 and 4 Gy) compared with low dose (0.4 Gy) and control. Interestingly, an apoptotic minority does seem to survive at 48 hours. Using a BLI technique, we confirmed that the higher doses of radiation cause hESCs to initially die after transplantation, but the surviving cells recover by 2 weeks to levels similar to control. Regardless of the radiation dose used in our study, all groups of irradiated hESCs were able to form teratomas, the definitive test of pluripotency. Our genome-wide analysis of gene expression revealed genes and pathways at each radiation dose that are involved in cell death, p53 signaling, cell cycling, cancer, embryonic and organ development, and others. Importantly, GSEA showed that the expression of a comprehensive set of core embryonic transcription factors is not significantly altered by radiation at any dose and helps explain how irradiated hESCs are still able to form teratomas.
In summary, this is the first study of hESC genome-wide transcriptional changes induced by ionizing radiation and is a preliminary step toward a better understanding of not only hESC molecular changes but also the in utero embryonic gene expression response. We have shown that, similar to somatic cells, irradiated hESCs suffer significant death and apoptosis after irradiation. Although some gene programs involved in developmental pathways are altered with high-dose radiation, the expression of pluripotency genes is unaffected, and these cells can still form teratomas. Studies such as this may help define the limits for radiation exposure for pregnant women and also radiotracer reporter probes for tracking cellular regenerative therapies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
We thank Pauline Chu and Andrew J. Connolly for assistance with tissue processing and histologic analysis.
Grant Support: Stanford Bio-X Fellowship (K.D. Wilson), R21 HL091453 (J.C. Wu), and R33 HL089027 (J.C. Wu).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.